New combo therapy offers hope for young patients with hard-to-treat lymphoma

This study tests a new treatment plan for children, teens, and young adults with a rare blood cancer (ALK+ anaplastic large cell lymphoma) that has come back or not responded to standard therapy. The approach combines an FDA-approved immunotherapy drug (nivolumab) with chemotherapy tailored to each patient's risk level, followed by a stem cell transplant from a donor. The goal is to improve survival and reduce side effects in this high-risk group.